AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place ...

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

AstraZeneca plans C$820 million investment in Canada to advance growing global hub and clinical delivery: Mississauga, Ontario Saturday, January 25, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

DUBAI, UAE - Media OutReach Newswire - 28 January 2025 - AstraZeneca, a leading multinational <a target=_blank href= ...

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...